New Customer 5% Off

Copy a coupon code below and apply it when checkout

5%
OFF
New Customer 5% Off
No expiration date
-25.757575757576% PURE HEALTH-EPO Click to enlarge

PURE HEALTH-EPO

$ 49.00

624sold

  • 💥💥Free shipping on orders of $1000 or more!
  • Get it between November 19 ~ November 24
  • Over 18 people have this in their carts right now
  • V*****u in New York, US United States bought this (2 Hours ago)

Total $ 49.00

Recent Orders
—
0
Name
Order
Quantity
Date
Trusted Store
99%Issue-Free
SecureCheckout
$10KID Protect

Payment Security

Privacy Protection

Efficient Shipping

Customer Support

product description

Erythropoietin (EPO / rhEPO, Epoetin Alfa)
Full Research Introduction & Administration Guide
IMPORTANT DISCLAIMER: For laboratory research use only. Not approved for human self-administration. EPO is listed as a prohibited performance-enhancing substance by WADA. Improper human usage causes severe cardiovascular risks including hypertension, thrombosis, stroke and fatal polycythemia.
Note: EPO is a glycosylated protein hormone, often categorized alongside research peptides.
1. Basic Overview
Full Name: Recombinant Human Erythropoietin (rhEPO / Epoetin Alfa)
Endogenous Origin: Primarily synthesized in renal interstitial fibroblasts under hypoxic conditions
Form: Lyophilized white/off-white crystalline powder
Common Research Unit: IU (International Units)
Core Feature: Primary regulator of erythropoiesis. Binds EPO receptors on bone marrow erythroid progenitor cells to stimulate red blood cell maturation. Exhibits secondary anti-apoptotic, anti-inflammatory, neuroprotective and cardioprotective effects in preclinical tissue injury models.
2. Mechanism of Action
Hematopoietic Pathway (Primary Effect)
EPO binds EPOR on erythroid precursor cells in bone marrow. Activates JAK2/STAT5, PI3K/Akt and MAPK signaling pathways to promote cell survival, proliferation and differentiation, elevating hemoglobin and hematocrit levels.
Non-Hematopoietic Tissue Protection
EPOR is widely expressed in brain, heart, kidney, retina and vascular endothelium. EPO reduces oxidative stress, inhibits caspase-mediated apoptosis and suppresses NF-κB inflammatory cascades in ischemia/reperfusion injury models.
Oxygen Homeostasis Feedback
Tissue hypoxia upregulates endogenous EPO expression; elevated red cell mass improves oxygen transport and suppresses further EPO production via negative feedback.
3. Main Research Applications
Preclinical anemia models (chronic kidney disease, chemotherapy-induced anemia, hemorrhage)
Cerebral ischemia, traumatic brain injury, stroke neuroprotection research
Myocardial infarction, cardiac ischemia reperfusion protection experiments
Retinal hypoxia and degenerative eye disease studies
Exercise physiology, oxygen transport and endurance animal trials
Hematopoietic stem cell biology research
4. Reconstitution Instructions
Recommended solvent: Bacteriostatic Water (BAC Water) or sterile 0.9% saline
Allow lyophilized vial to reach room temperature; sanitize rubber stopper with alcohol.
Slowly inject solvent along the inner glass wall to avoid protein denaturation and foaming.
Gently swirl to dissolve powder. DO NOT shake vigorously or vortex.
Qualified solution: clear colorless liquid. Discard if turbidity, flocculation or precipitation occurs.
Example: 5,000 IU lyophilized EPO + 1 mL BAC Water = 5,000 IU / mL concentration
Storage Protocol
Unreconstituted lyophilized powder: −20°C, protected from light; stable for up to 24 months. Avoid repeated freeze-thaw cycles.
Reconstituted solution: Refrigerate at 2–8°C; use within 14–21 days. DO NOT FREEZE reconstituted EPO (freezing triggers protein aggregation and irreversible loss of activity).
5. Preclinical Research Administration Protocols
Preferred route: Subcutaneous injection (SC); alternative: Intraperitoneal (IP) / Intravenous (IV)
Animal Dosage Reference (for experimental design only)
Low tissue-protective dose: 50–150 IU/kg body weight
Standard hematopoietic dose: 300–1000 IU/kg body weight
Frequency: 2–3 times weekly; typical experimental cycle: 14–28 days
Monitoring indicators: Hemoglobin (Hb), hematocrit (Hct), serum EPO concentration
Pharmacokinetics reminder: SC injection yields slower absorption and longer duration than IV injection.
6. Critical Precautions
Strictly for laboratory experimental purposes. Not for human administration.
Excessive dosing causes polycythemia: elevated blood viscosity, hypertension, increased risk of thrombosis, myocardial infarction and stroke.
Avoid concurrent use with other erythropoietic stimulating agents.
Monitor hematological parameters regularly during chronic animal studies. Cease administration if hematocrit rises excessively.
EPO is photosensitive; minimize exposure to strong light during handling and storage.
Aseptic technique is mandatory during all reconstitution and injection procedures.
Short Version (For Product Listing / Customer Message)
Erythropoietin (EPO / rhEPO)
Recombinant human Erythropoietin is a glycoprotein growth factor. It stimulates bone marrow red blood cell production to treat experimental anemia. It also demonstrates neuroprotective, cardioprotective and anti-inflammatory activity in ischemia research models.
Important Warning: EPO is a WADA-banned substance. Uncontrolled human use carries life-threatening cardiovascular risks.
Reconstitution Tips
Mix gently with bacteriostatic water or sterile saline. Never freeze reconstituted solution; store refrigerated and use within 21 days.

Product NamePURE HEALTH-EPO
Specification
Purity≥ 99%
FormLyophilized powder
StorageStore at -20°C in a cool, dry place

Reviews are currently unavailable.